The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
|Slideshows|October 31, 2015
Neuro News Roundup: Stroke
Author(s)Mark L. Fuerst
The following slides discuss strokes: the role of job stress and the stress doctors feel when treating cryptogenic strokes.
Advertisement
This month’s roundup looks at how to handle cryptogenic strokes and the role job stress plays in stroke risk.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
3
GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial
4
Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD
5